Closed
The Marked Chart Wire · Health
Argenx
Argenx plans to submit a supplemental biologic license application for efgartigimod to treat immune-mediated nodular melanoma by the end of 2026. The move follows a Phase 3 trial showing a 14.8-point greater improvement in a disease measure versus placebo at week 52.
Prices from Before the open · based on Fri close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
CRISPR Therapeutics
CRISPR Therapeutics said 83 percent of systemic sclerosis patients reached a response target at three months with zugo-cel, while all nine myositis patients achieved moderate or major improvement.
Prostate Cancer
Johnson & Johnson said its experimental drugs pasritamig and JNJ-9401 achieved a 73 percent PSA response in a phase 1 prostate cancer study. The trial recorded no serious side effects, supporting outpatient dosing.
Lupus Drug
UCB and Biogen say their lupus treatment dapirolizumab pegol achieved higher response rates than placebo in post-hoc analyses of phase 3 trial data.
Valneva
Valneva reported that its S4V2 immunization achieved its main goal in a phase 2 study, significantly lowering infection rates compared to a placebo. A separate infant study also showed positive safety data.
Mineralys Therapeutics
Mineralys Therapeutics said lorundrostat lowered systolic blood pressure by 17.8 mmHg at week 48 in a phase 3 trial extension. About 56 percent of patients reached levels below 130 mmHg.
FDA Approval
The FDA has approved daraxonrasib from Revolution Medicines for the treatment of pancreatic cancer.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.